Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders' Equity/Deficit

v3.21.1
Consolidated Statements of Shareholders' Equity/Deficit - USD ($)
Preferred Stock
Common Stock
Additional Paid-in Capital
Retained Earnings
Total
Noncontrolling Interest
Total
Equity Balance, Starting at Dec. 31, 2018 $ 0 $ 2,314 $ 13,071,626 $ (6,438,316) $ 6,635,624 $ (201,784) $ 6,433,840
Shares Outstanding, Starting at Dec. 31, 2018 11 23,139,837          
Distribution $ 0 $ 0 0 0 0 (2,524) (2,524)
Net Income (Loss) $ 0 $ 0 0 (3,436,890) (3,436,890) 18,258 (3,418,632)
Shares Outstanding, Ending at Dec. 31, 2019 11 22,850,947          
Equity Balance, Ending at Dec. 31, 2019 $ 0 $ 2,285 13,071,655 (9,875,206) 3,198,734 (186,050) 3,012,684
Rescind sale of common stock to G Farma, Value $ 0 $ (29) 29 0 0 0 0
Rescind sale of common stock to G Farma, Shares 0 (288,890)          
Net Income (Loss) $ 0 $ 0 0 (726,025) (726,025) 48,484 (677,541)
Shares Outstanding, Ending at Dec. 31, 2020 11 22,850,947          
Equity Balance, Ending at Dec. 31, 2020 $ 0 $ 2,285 $ 13,071,655 $ (10,601,231) $ 2,472,709 $ (137,566) $ 2,335,143